The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis - 05/02/16
, Noel G. McElvaney, MD aAbstract |
Background |
Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized subjects, a response that can be readily measured by using flow cytometry.
Objective |
We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT).
Methods |
Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus–specific IgE), pulmonary function, and body mass index measurements were performed.
Results |
The BAT discriminates A fumigatus–sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus–stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus–sensitized but not nonsensitized patients with CF. Total and A fumigatus–specific IgE, but not IgG, levels are increased in A fumigatus–sensitized patients with CF and ABPA when compared with those in A fumigatus–sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization.
Conclusion |
Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus–sensitized, and ABPA. Accurate and prompt identification of A fumigatus–associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes.
Le texte complet de cet article est disponible en PDF.Key words : Allergic bronchopulmonary aspergillosis, Aspergillus fumigatus, basophil activation test, body mass index, CD203c, cystic fibrosis, flow cytometry, FEV1, itraconazole, sensitization
Abbreviations used : ABPA, BAT, BMI, CF, GM, ROC, sIgE, sIgG, SPT
Plan
| Supported by Science Foundation Ireland via a United States–Ireland partnership (grant no. SFI/08/US/B1676) and by the US Cystic Fibrosis Foundation. |
|
| Disclosure of potential conflict of interest: P. Murphy has received research support from the National Clinical Research Centre and Crumlin Hospital Dublin, has been supported by a National Children's Hospital joint grant on Metagenomics in Cystic Fibrosis, and is a board member for and has received travel support from Novartis. N. G. McElvaney has received research support from the Health Research Board and Science Foundation Ireland and has received consultancy fees from Chiesi and CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 2
P. 436 - février 2016 Retour au numéro
Article précédent
- Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells
- Jae-Uoong Shim, Shee Eun Lee, Won Hwang, Changhon Lee, Jung-Won Park, Jung-Ho Sohn, Jong Hee Nam, Young Kim, Joon Haeng Rhee, Sin-Hyeog Im, Young-Il Koh
- Benign TH2 immunity in children: A fresh perspective on control of the allergic response
- Judith A. Woodfolk
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?